Lakhani S.R. International Agency for Research on Cancer2nd edition. WHO classification of breast tumours: WHO classification of tumours. vol. 2. IARC, Lyon, France ()London S.J. Connolly J.L. Schnitt S.J. et al.

A prospective study of benign breast disease and the risk of breast cancer.

JAMA. 267: 941-944Page D.L. Dupont W.D. Rogers L.W. et al.

Atypical hyperplastic lesions of the female breast: a long-term follow-up study.

Cancer. 55: 2698-2708Simpson P.T. Gale T. Fulford L.G. et al.

The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ.

Breast Cancer Res. 5: 258-262

Neoplastic diseases: a textbook on tumors.

WB Saunders, PhiladelphiaFoote Jr., F.W. Stewart F.W.

Lobular carcinoma in situ. A rare form of mammary cancer.

Am J Pathol. 17: 491-496Haagensen C.D. Lane N. Lattes R. et al.

Lobular neoplasia (so-called lobular carcinoma in situ) of the breast.

Cancer. 42: 737-769Lee J.Y. Schizas M. Geyer F.C. et al.

Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Clin Cancer Res. 25: 674-686Andrade V.P. Ostrovnaya I. Seshan V.E. et al.

Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions.

Breast Cancer Res. 14: R103Begg C.B. Ostrovnaya I. Carniello J.V. et al.

Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Breast Cancer Res. 18: 66

National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis.

() ()

Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia.

Hum Pathol. 23: 1095-1097Jain R.K. Mehta R. Dimitrov R. et al.

Atypical ductal hyperplasia: interobserver and intraobserver variability.

Mod Pathol. 24: 917-923Chen Y.Y.D.T. King T.A. Palacios J. et al.

Lobular carcinoma in situ.

in: Board T.W.C.E. Breast Tumours. International Agency for Research on Cancer, Lyon (France): 71-74Chen Y.Y. Hwang E.S. Roy R. et al.

Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.

Am J Surg Pathol. 33: 1683-1694Dabbs D.J. Schnitt S.J. Geyer F.C. et al.

Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.

Am J Surg Pathol. 37: 1-11Beute B.J. Kalisher L. Hutter R.V.

Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features.

AJR Am J Roentgenol. 157: 257-265Maxwell A.J. Clements K. Dodwell D.J. et al.

The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.

Breast. 27: 109-115Eusebi V. Magalhaes F. Azzopardi J.G.

Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation.

Hum Pathol. 23: 655-662Sneige N. Wang J. Baker B.A. et al.

Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.

Mod Pathol. 15: 1044-1050Alvarado-Cabrero I. Picon Coronel G. Valencia Cedillo R. et al.

Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: a clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma.

Arch Med Res. 41: 436-441Shamir E.R. Chen Y.Y. Chu T. et al.

Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center.

Am J Surg Pathol. 43: 399-408Lopez-Garcia M.A. Geyer F.C. Lacroix-Triki M. et al.

Breast cancer precursors revisited: molecular features and progression pathways.

Histopathology. 57: 171-192Mastracci T. Tjan S. Bane A. et al.

E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast.

Mod Pathol. 18: 741-751Sarrio D. Moreno-Bueno G. Hardisson D. et al.

Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability.

Int J Cancer. 106: 208-215Derksen P.W. Liu X. Saridin F. et al.

Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Cancer Cell. 10: 437-449Weigelt B. Geyer F.C. Natrajan R. et al.

The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

J Pathol. 220: 45-57Lu Y.J. Osin P. Lakhani S.R. et al.

Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.

Cancer Res. 58: 4721-4727Ciriello G. Gatza M.L. Beck A.H. et al.

Comprehensive molecular portraits of invasive lobular breast cancer.

Cell. 163: 506-519Swanton C. McGranahan N. Starrett G.J. et al.

APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity.

Cancer Discov. 5: 704-712Li C.I. Malone K.E. Saltzman B.S. et al.

Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001.

Cancer. 106: 2104-2112Reis-Filho J.S. Pusztai L.

Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Lancet. 378: 1812-1823

Risk factors for breast cancer in women with proliferative breast disease.

N Engl J Med. 312: 146-151Hartmann L.C. Schaid D.J. Woods J.E. et al.

Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

N Engl J Med. 340: 77-84Page D.L. Kidd Jr., T.E. Dupont W.D. et al.

Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease.

Hum Pathol. 22: 1232-1239King T.A. Pilewskie M. Muhsen S. et al.

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

J Clin Oncol. 33: 3945-3952Bodian C.A. Perzin K.H. Lattes R.

Lobular neoplasia. Long term risk of breast cancer and relation to other factors.

Cancer. 78: 1024-1034Chuba P.J. Hamre M.R. Yap J. et al.

Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of Surveillance, Epidemiology, and End Results data.

J Clin Oncol. 23: 5534-5541Collins L.C. Aroner S.A. Connolly J.L. et al.

Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.

Cancer. 122: 515-520Degnim A.C. Dupont W.D. Radisky D.C. et al.

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Cancer. 122: 2971-2978Valero M.G. Zabor E.C. Park A. et al.

The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.

Ann Surg Oncol. 27: 736-740Pankratz V.S. Hartmann L.C. Degnim A.C. et al.

Assessment of the accuracy of the Gail model in women with atypical hyperplasia.

J Clin Oncol. 26: 5374-5379

Lobular carcinoma in situ of the breast.

Breast J. 5: 296-303

Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast: A review.

Eur J Surg Oncol. 37: 279-289Portschy P.R. Marmor S. Nzara R. et al.

Trends in incidence and management of lobular carcinoma in situ: A population-based analysis.

Ann Surg Oncol. 20: 3240-3246

The American Society of Breast Surgeons. Position Statement on Screening Mammography.

() ()Hwang H. Barke L.D. Mendelson E.B. et al.

Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary.

Mod Pathol. 21: 1208-1216Menon S. Porter G.J. Evans A.J. et al.

The significance of lobular neoplasia on needle core biopsy of the breast.

Virch Arch. 452: 473-479Purdie C.A. McLean D. Stormonth E. et al.

Management of in situ lobular neoplasia detected on needle core biopsy of breast.

J Clin Pathol. 63: 987-993Niell B. Specht M. Gerade B. et al.

Is excisional biopsy required after a breast core biopsy yields lobular neoplasia?.

AJR Am J Roentgenol. 199: 929-935Rendi M.H. Dintzis S.M. Lehman C.D. et al.

Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy.

Ann Surg Oncol. 19: 914-921Shah-Khan M.G. Geiger X.J. Reynolds C. et al.

Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy.

Ann Surg Oncol. 19: 3131-3138Atkins K.A. Cohen M.A. Nicholson B. et al.

Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation.

Radiology. 269: 340-347Chaudhary S. Lawrence L. McGinty G. et al.

Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy.

Mod Pathol. 26: 762-771Murray M.P. Luedtke C. Liberman L. et al.

Classic lobular carcinoma in situ and atypical lobular hy- perplasia at percutaneous breast core biopsy: outcomes of prospective excision.

Cancer. 119: 1073-1079Mooney K.L. Bassett L.W. Apple S.K.

Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Mod Pathol. 29: 1471-1484Nakhlis F. Gilmore L. Gelman R. et al.

Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in-situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020).

Ann Surg Oncol. 23: 722-728Sen L.Q. Berg W.A. Hooley R.J. et al.

Core breast biopsies showing lobular carcinoma in situ should be excised and surveillance is reasonable for atypical lobular hyperplasia.

AJR Am J Roentgenol. 207: 1132-1145Susnik B. Day D. Abeln E. et al.

Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases.

Clin Breast Cancer. 16: 507-513Muller K.E. Roberts E. Zhao L. et al.

Isolated atypical lobular hyperplasia diagnosed on breast biopsy: low upgrade rate on subse- quent excision with long-term follow-up.

Arch Pathol Lab Med. 142: 391-395Schmidt H. Arditi B. Wooster M. et al.

Observation versus excision of lobular neoplasia on core needle biopsy of the breast.

Breast Cancer Res Treat. 168: 649-654Holbrook A.I. Hanley K. Jeffers C. et al.

Triaging Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Percutaneous Core Biopsy to Surgery or Observation: Assiduous Radiologic-Pathologic Correlation Works, Quantitating Extent of Disease Does Not.

Arch Pathol Lab Med. 143: 621-627Li X. Ma Z. Styblo T.M. Arciero C.A. Wang H. Cohen M.A.

Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high risk breast lesion conferences at an academic institution. Breast cancer research and.

treatment. 185: 573-581Pride R.M. Jimenez R.E. Hoskin T.L. et al.

Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ.

Surgery. 169: 644-648Laws A. Katlin F. Nakhlis F. et al.

Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision.

Ann Surg Oncol. 29: 1660-1667Nakhlis F. Harrison B.T. Giess C.S. et al.

Evaluating the rate of upgrade to invasive breast cancer and/or ductal carcinoma in situ following a core biopsy diagnosis of non-classic lobular carcinoma in situ.

Ann Surg Oncol. 26: 55-61Kuba M.G. Murray M.P. Coffey K. et al.

Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.

Mod Pathol. 34: 1495-1506Flanagan M.R. Rendi M.H. Calhoun K.E. et al.

Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management.

Ann Surg Oncol. 22: 4263-4269Downs-Kelly E. Bell D. Perkins G.H. et al.

Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ.

Arch Pathol Lab Med. 135: 737-743Sullivan M.E. Khan S.A. Sullu Y. et al.

Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications.

Arch Pathol Lab Med. 134: 1024-1028Chivukula M. Haynik D.M. Brufsky A. et al.

Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.

Am J Surg Pathol. 32: 1721-1726Blair S.L. Emerson D.K. Kulkarni S. et al.

Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ.

Breast J. 19: 116-118

Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast conservation therapy.

Int J Radiat Oncol Biol Phys. 40: 353-358Khoury T. Karabakhtsian R.G. Mattson D. et al.

Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases.

Histopathology. 64: 981-993Monticciolo D.L. Newell M.S. Moy L. et al.

Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR.

J Am Coll Radiol. 15: 408-414

American Cancer Society. Lobular Carcinoma in Situ.

() ()Nadler M. Al-Attar H. Warner E. et al.

MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.

Breast. 34: 77-82King T.A. Muhsen S. Patil S. et al.

Is there a role for routine screening MRI in women with LCIS?.

Breast Cancer Res Treat. 142: 445-453Tilanus-Linthorst M.M. Obdeijn I.M. Hop W.C. et al.

BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.

Clin Cancer Res. 13: 7357-7362Fisher B. Costantino J.P. Wickerham D.L. et al.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

J Natl Cancer Inst. 90: 1371-1388Vogel V.G. Costantino J.P. Wickerham D.L. et al.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

JAMA. 295: 2727-2741Goss P.E. Ingle J.N. Ales-Martinez J.E. et al.

Exemestane for breast-cancer prevention in postmenopausal women.

N Engl J Med. 364: 2381-2391Cuzick J. Sestak I. Forbes J.F. et al.

IBIS-II investigators. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.

Lancet. 395: 117-122Noonan S. Pasa A. Fontana V. et al.

A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene.

Cancer Prev Res (Phila). 11: 38-43Land S.R. Walcott F.L. Liu Q. et al.

Symptoms and QOL as predictors of chemoprevention adherence in NRG Oncology/NSABP Trial P-1.

J Natl Cancer Inst. 108: djv365Ropka M.E. Keim J. Philbrick J.T.

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.

J Clin Oncol. 28: 3090-3095Port E.R. Montgomery L.L. Heerdt A.S. et al.

Patient reluctance toward tamoxifen use for breast cancer primary prevention.

Ann Surg Oncol. 8: 580-585Bambhroliya A. Chavez-MacGregor M. Brewster A.M.

Barriers to the use of breast cancer risk reduction therapies.

J Natl Compr Canc Netw. 13: 927-935Brewster A.M. Thomas P. Brown P. et al.

A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ.

Cancer Prev Res. 11: 295-302DeCensi A. Puntoni M. Guerrieri-Gonzaga A. et al.

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.

J Clin Oncol. 37: 1629-1637Taylor L.J. Steiman J. Schumacher J.R. et al.

Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.

Ann Surg Oncol. 25: 2229-2234Geiger A.M. Yu O. Herrinton L.J. et al.

A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.

Arch Intern Med. 165: 516-520Sakurai T. Zhang N. Suzuma T. et al.

Long-term follow-up of nipple-sparing mastectomy without radiotherapy: a single center study at a Japanese institution.

Med Oncol. 30: 481Jakub J.W. Peled A.W. Gray R.J. et al.

Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.

JAMA Surg. 153: 123-129Balch C. Klimberg V.S. Pawlik T. et al.

Textbook of complex general surgical oncology.

McGraw-Hill, New York, USA